K-8008, as a sulindac-derived RXRα ligand, could inhibit the 9-cis-retinoic acid (9-cis-RA)-induced transactivation of RXRα and exert potent anti-cancer activity in breast cancer cells and animal models [4]. Here, RXRA is linked to breast carcinoma.